Indication
Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs)
and
adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
Medicine details
- Medicine name:
- bimekizumab (Bimzelx)
- SMC ID:
- SMC2616
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Abbreviated
- Publication due date:
- 11 December 2023